Even though the role of estrogen receptor alpha (ERα) 
Introduction
Breast cancer is the most prevalent type of cancer among women, worldwide with the hormone receptor-positive tumor being present in most breast cancer patients [1] .
Estrogen receptors (ERs) are among the principal signaling molecules that regulate several cell functions, acting either through the genomic or through the non-genomic pathway [2] [3] [4] . Cell signaling via the estradiol (E2)-ER axis affects also the cell behavior and the expression of the extracellular matrix (ECM) macromolecules, thus altering the tumor microenvironment. ECM is a dynamic scaffold, consisting of a variety of functional components, such as proteoglycans, glycoproteins and proteinases [5] [6] [7] [8] [9] [10] [11] [12] . This network provides structural stability but could also mediate tumor development and progression through interactions between its macromolecules [13] [14] [15] [16] [17] [18] [19] . Alterations in the expression of matrix components result in the remodeling of ECM, thus affecting its ability to regulate several important functions of cancer cells, such as proliferation, migration, adhesion and invasion [10, [20] [21] [22] [23] [24] [25] [26] [27] . The expression of major matrix macromolecules is affected by ERs suggesting a critical role of endocrine regulation for the tumor microenvironment and thus the functional properties of breast cancer cells [28] [29] [30] [31] . Using the ERα-negative and ERβ-positive, highly invasive MDA-MB-231 breast cancer cells, we have recently established a stable transfected ERβ-suppressed cell line (named shERβ MDA-MB-231) [32] . The suppression of ERβ in MDA-MB-231 breast cancer cells evoked striking changes in the gene and protein expression levels of significant ECM components, such as proteoglycans, matrix degrading enzymes, cell surface receptors and signalling molecules, which in turn mediated the behaviour of breast cancer cells. In addition, the suppression of ERβ in these cells inhibited epithelial-to-mesenchymal transition (EMT), a critical process for the initiation of metastasis [33, 34] , leading to a less aggressive phenotype with decreased cell proliferation, migration and invasion potential [32] .
Of particular interest in the understanding of cancer cell behavior is the field of microRNAs (miRNAs). They are endogenous non-coding RNA molecules, which have an important roles in post-transcriptional regulation of a broad set of a wide range of numerous cellular processes [35, 36] . By binding of their 'seed' region to the 3'-untranslated region of target mRNAs, miRNAs are capable of either inducing mRNA degradation via the RNA-induced silencing complex, or of inhibiting mRNA translation [37] . During the last decade, several reports associated the altered expression of various
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miRNAs with cell proliferation, resistance to apoptosis, differentiation, immunity and cancer initiation, progression and metastasis. MiRNAs can directly modulate the EMT program and it is well established that ERα and ERβ genes are among the direct targets of several miRNAs [38] [39] [40] [41] . Moreover, miRNAs are responsible for the regulation of ECM components and of their cellular receptors. In breast cancer, overexpression of the transmembrane heparan sulfate proteoglycan (HSPG) syndecan-1, a predicted target of the pro-metastatic miR-10b, correlates with poor clinical outcome [42, 43] . Recent study has proven that the onco-miR-10b targets specifically syndecan-1 in breast cancer, highlighting the functional relationship or miRNAs and proteoglycans as well as indicating new evidence for the development of new therapeutic approaches for breast cancer [44] . On the other hand, miR-200b is a negative regulator of the EMT process and cancer metastasis. Several reports demonstrated that decreased expression levels of miR-200b are correlated with metastatic breast cancer and poor clinical outcome [45, 46] . There is contradicting evidence regarding the role of miR-145 in breast cancer progression. However, several reports reveal that miR-145 is responsible for the increased apoptosis in cancer cells as well as the decreased cell proliferation, proposing it as a putative tumor suppressor [47] [48] [49] [50] . MicroRNA-dependent modulation of the ECM and its cellular receptors has emerged as a novel mechanism of regulating numerous matrix-dependent processes, including cell proliferation and apoptosis, cell adhesion and migration and cell differentiation and have been proposed as a promising target for the development of new therapeutic approaches for breast cancer [51] .
In response to the above, we evaluated whether the different ER status could have an impact on the expression profiles of certain miRNAs and on the other hand to investigate the effect of ER-related miRNAs on the basic functional properties, EMT program and matrix composition of breast cancer cells. For these purposes, we utilized the ERα- 
MB-231 cells
It has been previously demonstrated that miR-10b expression is upregulated in clinical samples of metastatic breast cancer [52] . Moreover, miR-10b silencing inhibits breast
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cancer metastasis in vivo in a mouse mammary tumor model [53] . decreased expression, as a disrupted F-actin network with elongated filaments can be observed (Fig. 5D ).
Previous studies demonstrated that miR-145 suppresses growth and migration in breast cancer clinical samples relative to normal breast tissue and that the overexpression of miR-145 strongly inhibited EMT [57, 58] . To this end, using confocal microscopy we observed that the inhibition of miR-145 in shERβ MDA-MB-231 breast cancer cells evokes the decrease of E-cadherin and the increase of vimentin protein levels (Fig. 6A) .
Moreover, anti-miR-145 results in the strong downregulation of E-cadherin and the significant increase of vimentin, fibronectin and Snail2/Slug expression levels in shERβ MDA-MB-231 cells (Fig. 6B) . Notably, in control MDA-MB-231 cells anti-miR-145 has no effect on the expression profiles of E-cadherin and vimentin, but it increased the expression levels of fibronectin and Snail2/Slug, enhancing their aggressive phenotype. 
Discussion
It is well established that miRNAs are powerful mediators of the development, metastasis and progression of breast cancer, therefore the investigation of their functions is of great clinical relevance and may provide novel targets for therapeutic approaches in breast cancer [36, 59] . The miRNA processing pathway has long been viewed as linear and universal to all mammalian miRNAs [37] . Numerous miRNAs have been identified as regulators of breast cancer cell properties [60] [61] [62] . While some miRNAs act as tumor suppressors, others act as oncogenes, depending on their respective molecular targets. MiR-10b has been demonstrated as a pro-metastatic miRNA as it positively regulates cell migration and invasion in vitro and it initiates tumor invasion in vivo [41, 63, 64] . Moreover, its expression levels are elevated in metastatic breast cancers [41, 44] . Importantly, the mRNAs encoding ERα and ERβ are targets of this miRNA [38] . In contrast to the onco-miR-10b, miR-200b is linked to the mesenchymal phenotype of breast cancer cells, as it is one of the negative regulators of the EMT process, invasion and metastasis [39, 65] . Downregulated expression levels of this miRNA can be found in metastatic and breast cancer stem cell-like cells in vitro [66, 67] . Moreover, it is demonstrated that members of the miR-200 family target directly ERα and ERβ [68] . There is contradicting evidence regarding the role of miR-145 in breast cancer. However, several reports reveal that miR-145 is responsible for the increased apoptosis in cancer cells as well as the decreased cell proliferation, proposing it as a putative tumor suppressor [47] [48] [49] [50] .
In this study, we evaluated the miRNA regulation in the EMT process and the functional properties of shERβ MDA-MB-231 breast cancer cells. We pinpointed that miR-10b and miR-145 were among the most significantly deregulated miRNAs after the suppression of ERβ in shERβ MDA-MB-231 cells. These miRNAs are closely linked to the EMT program and could contribute to cell-cell and/or cell-ECM interactions, affecting crucial breast cancer cells properties [69] . The obtained data showed that miR-10b, which is overexpressed in clinical samples of metastatic breast cancer and positively regulates
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tumor invasion in vivo [63] , is significantly downregulated in shERβ MDA-MB-231 cells, as compared to MDA-MB-231cells.
Consistent with the ERα-dependent expression, E2 has a positive role in this regulation, as its absence from the culture medium significantly increased miR-10b expression levels in MCF-7 cells. Accordingly, miR-200b, which is negative modulator of tumor invasion and metastasis [66] , has been found to be significantly upregulated in MCF-7
and It has been previously described that miR-10b promotes the invasiveness of breast cancer cells [70] . Interestingly, the induction of its expression by transfecting shERβ MDA-MB-231 cells with pre-miR-10b caused a significant increase in proliferation, migration and invasion rates of these cells. Moreover, the induction of miR-10b expression resulted in important changes in cell morphology, EMT markers, as well as expression of cell surface receptors, ECM components, including syndecan-1, which is a target of miR-10b [44] , and proteolytic enzymes such as MMP2, MMP7 and MMP9.
These alterations were accompanied by the strong increase in the phosphorylated levels of Erk1/2 kinase, which has been correlated with breast cancer cell growth and motility [71] , suggesting the critical role of miR-10b in this signaling pathway. These data suggest that the low expression levels of miR-10b following the ERβ suppression - 
microRNA transfection
Transfections of ΜDA-MB-231 empty vector and shERβ ΜDA-MB-231 cells with the miRNA precursor pre-miR-10b, or the miRNA inhibitor anti-miR-145 (10nM, ABI, Darmstadt, Germany), or miR negative control (10nM, ABI) were performed according to the manufacturer's instructions and as described previously [47] .
MTT cell proliferation assay
Breast cancer cells were seeded in 96-well plates (5,000 cells/well) 48h after the miRNA transfections and cultured for additional 48h. MTT assay was performed as described previously [47] .
In vitro invasion assay
In total, 25,000 breast cancer cells in 0.5 mL DMEM/10% FCS were added in triplicates to the upper compartments of Matrigel Invasion Chambers (BD Biosciences, Heidelberg, Germany) 48h after miRNA transfections. After 24h, the medium in the upper chamber was replaced by serum-free DMEM. After 48h, cells on the lower surface were fixed and stained with DiffQuik (Medion, Duedingen, Switzerland). Relative invasiveness was expressed as percentage of cells on compound-treated compared to control inserts (n > 3).
In vitro wound healing assay
Transfected breast cancer cells were seeded in 12-well cell culture plates at a density of 25,000 cells/well. Breast cancer confluent cell layers were serum starved for 16 h and then wounded by scratching with a sterile 100 μL pipette tip. Detached cells were removed by washing twice with PBS and fresh culture medium, in the absence of serum, was added. The wound closure was monitored at 0, 16 and 24 h using a digital camera
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connected to a microscope. Wound surface area was quantified by image analysis (Image J software).
RNA isolation and real-time PCR analysis
Total cellular RNA was isolated using rna-OLS (OMNI Life Science, Hamburg, Germany) and reverse transcribed (Advantage First strand cDNA synthesis kit; Fermentas, St.
Leon-Rot, Germany). For miRNA isolation and analysis, the mirVanaTM miRNA Isolation Kit (ABI) and the TaqManVR MicroRNA RT kit (ABI) were employed. Quantitative realtime PCR (qPCR) and melting curve analysis were performed using Qiagen QuantiTect SYBR Green PCR kit in a LightCycler (Roche, IN). Expression of miRNAs and additional mRNAs was analyzed using TaqMan probes on an ABI PRISM 7300 Sequence
Detection System as described previously [47] . The 2 -ΔΔCt method was used to determine relative gene transcript levels after normalization to 18S rRNA. Primer sequences, QuantiTect assay and TaqMan probe IDs are listed in Supplementary   Tables 2 and 3 .
Confocal immunofluorescence microscopy
Transfected breast cancer cells were seeded onto coverslips in 24-well plate and Netherlands) operating in secondary-electron mode.
Western blot analysis
Cell lysates of breast cancer cells were prepared 72h after transfection with control or miRNAs as described previously [72] . Cell lysates were separated on 10% SDS-PAGE, the proteins were electrophoretically transferred to PVDF membranes (Bio-Rad, USA)
and blotted with the indicated antibodies as described previously [72] , using 30-60 μg of protein/lane.
Statistical analysis
Reported values are expressed as mean ± standard deviation (SD) of experiments in triplicate. Statistically significant differences were evaluated using the analysis of variance (ANOVA) test and were considered statistically significant at the level of at least p ≤ 0.05. Statistical analysis and graphs were made using GraphPad Prism 6 (GraphPad Software).
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